Partnering With Industry for Clinical Research Luke Lin, MD, and Ralf Schnall.

Slides:



Advertisements
Similar presentations
CMRSC Division of Hematology/Oncology
Advertisements

Project Quality Plans Gillian Sandilands Director of Quality
Mary Ellen Turner MD, MPH Vice-President
Session No. 4 Implementing the State’s Safety Programme Implementing Service Providers SMS
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
EHR stakeholder workshop – 11th October EHR integration for clinical research: toward new interaction models ? Isabelle de Zegher.
MEETING OF THE FEDERAL PARTNERS IN TECHNOLOGY TRANSFER (FPTT) – NATIONAL JUNE 1 ST 2005 EILEEN RAYMOND – INDUSTRIAL AFFAIRS.
SUCCESSFULLY EMBRACING CHANGES TO CDISC STANDARDS Dr. Elke Sennewald Director, Biometrics Operating Standards Group.
Principal Patent Analyst
LEARNING WHICH REGULATORY STANDARDS ARE NON-STANDARD Bert Spilker, PhD, MD President, Bert Spilker & Associates.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
NATIONAL CAPACITY BUILDING FORTHE DEVELOPMENT OF A NATIONAL IMPLEMENTATION STRATEGY FOR THE GLOBALLY HARMONISED SYSTEM OF CLASSIFICATION AND LABELLING.
30 June 2015, 17:10:39 FP7 Network of Focal Points in Egypt (to be) Yasser Elshayeb Technical Office Ministry of Higher Education and State for Scientific.
| LUMIS International GmbH | Successful conduct of clinical trials to prove biosimilarity through defining a best fit outsourcing strategy Heike Schoen,
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Management of Change Control. Overview Changes – Good or bad? Forced or voluntary? The Importance of Change Control Major Changes to both legacy company.
Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.
Lowell Smith Sr. Director, Business & Communications Research Administration.
EMERGING AND RE-EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA - AVIESAN Workshop June 19th 2012, European Parliament, Bruxelles.
Paul Mundy Concept notes A brief summary of your project idea.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,
Copyright © 2013 Quintiles Quintiles Site Management Kim Davis, SSRM June 17, 2014.
Access to Clinical Expertise Steve Bain David Powell Jemma Hughes Paula Jeffries.
Valid Informed Consent Education Pilot Project 2 nd Annual Nursing Research & Evidence-Based Practice Symposium Sandra Knowlton-Soho, MS, RN Sara Simeone,
Pharmacovigilance obligations of the Pharmaceutical companies in India
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.
WIPO Pilot Project - Assisting Member States to Create an Adequate Innovation Infrastructure to Support University – Industry Collaboration.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Steps to Advance The SUNY Research & Innovation Ecosystem Jeffrey Boyce Research Foundation of SUNY Office of the Executive Vice President SUNY Board of.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
An R&D Manager’s Perspective TechExpo October 5, 2004 Presented by: Veena Rawat.
R&D – a perspective Dr Nana Theodorou Research Coordinator Sheffield Clinical Research Office.
This presentation is Proprietary and no portion of it may be utilized without the permission of Bio- Investigations Ltd. ENHANCING THE VALUATION OF EXTERNALLY-DERIVED.
Commons, Networks, and Technology Transfer Gerald Barnett Director, Intellectual Property Management University of California, Santa Cruz.
NIHR Research Design Service London Enabling Better Research Dr Caroline Burgess General Adviser 13 th November 2013.
Agenda for Session Compliance in Clinical Research
FDA Regulatory and Compliance Symposium
Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
NEUROGEN CORPORATION Alliance Management: View from the Smaller Side of the Alliance Thomas A. Pitler, Ph.D. VP Business Development.
NJE sugnHR1 Michael Conway ) David Quigley 2004 Pharma, Biotech and Device.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Horizon 2020 – 2016 Transport Call
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
Project design – Activities and partnership CENTRAL EUROPE PROGRAMME Project development seminar Prague, 1-2 February 2010 Monika Schönerklee-Grasser.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No Advanced European.
Experience from H2020 Proposals (a personal assessment)
Contents ARCI basics What does ARCI mean? How to read an ARCI chart Understanding the context and integration of an example ARCI (using an R&D function)
Rob Connatser NSS Instrument Work Packages and XLPM.
Clinical Trials.
Diane Trimble, MSN, RN-BC Saint Luke’s Health System.
The Essentia Institute of Rural Health (EIRH) is
VenaSeal Closure System Utilization of the Pre-Submission Process & Interactive Review Sponsor’s Perspective 24 February 2015.
SUNY Applied Learning Campus Plan Parts V-VII
Within Trial Decisions: Unblinding and Termination
1/22/2015 A partnership/collaboration from Bayer through setting up and implementing a global FSP strategy on a local level Keith Francis, Strategic.
Engineering Noontime Session March 18, :00-1:00 PM
The Food Talent Network
Introduction to TransCelerate
Timothy B. Cleary, Esq. Meredith Manning, Esq.
REAL WORLD CASE STUDY.
Code of Ethics for CDM Professionals
Code of Ethics for CDM Professionals
Presentation transcript:

Partnering With Industry for Clinical Research Luke Lin, MD, and Ralf Schnall

Two trends in the research and development of new therapies have been observed over the past several decades, resulting in the expansion of academic-industry partnerships Academia: Commercialization of discoveries from basic research into medical products for the marketplace Industry: Externalization of the search for innovative R&D approaches and scientific knowledge in order to expand the capacity Trends in Academic-Industry Partnerships Collaboration is central to this partnership

HOW CAN YOU PARTNER WITH INDUSTRY?

Investigator-Initiated Study Idea and proposal for a study from an external physician Sponsor is one or several physicians Pharma industry supports

Goals of doing IIS, BI perspective Generating scientific data, development programme not sufficient Detecting new signals of safety and/or efficacy in the same or new indications Benefitting of your scientific knowledge Achieving a potential label extension Getting publications Often cheaper than own trials

MAC Interactions Med Affairs Coordinator (MAC) Sponsor- Investigator Clinical Safety Officer (CSO) Med Director/ delegate TM MA IIS-RC (IIS Release Committee) IIS-RG (IIS Review Group) Local affiliate Global BI Investigator

MAC – Key Responsibilities Ensure that the Sponsor-Investigator is qualified Negotiate the IIS contract between the responsible OPU and the Sponsor-Investigator Ensure that Safety Reporting Responsibilities are described in the agreement Ensure transparency of study conduct and data dissemination

IIS Process 8 Investigator BI Investigator hands in a proposal

9 Investigator Local Medical Affairs Assessment of the study proposal Scientific rationale Statistical design Company strategy (Trial Guidance Document) Local regulations Local resources Budget Prepare for Corporate Review IIS Process

10 Corporate Medical Affairs IIS Manager Thorough assessment of the study proposal Completeness Prepare for Corporate Review Proposal number Investigator Local Medical Affairs IIS Process

11 Corporate Medical Affairs IIS Manager IIS Review Group Thorough assessment of the study proposal Monthly meeting MAC presents study to global team Scientific rationale Statistical design Company strategy Budget Monthly meeting Investigator Local Medical Affairs IIS Process

12 Corporate Medical Affairs IIS Manager IIS Review Group Possibility 1: Rejection Investigator Local Medical Affairs Monthly meeting IIS Process Rejection

Monthly meeting 13 IIS Review Group Possibility 2: After some major issues have been resolved, ready for re-review After some minor issues have been resolved, ready for release IIS Release Committee Monthly meeting  12 days after RG Corporate Medical Affairs IIS Manager Investigator Local Medical Affairs Next month RG Next month RC IIS Process Comments

14 Possibility 3: Ready for release IIS Review Group IIS Release Committee Monthly meeting  12 days after RG Investigator Local Medical Affairs IIS Process Monthly meeting Corporate Medical Affairs IIS Manager

15 Assessment of the study proposal Monthly meeting Company strategy Budget Final Decision IIS Review Group IIS Release Committee Monthly meeting  12 days after RG Investigator Local Medical Affairs IIS Process Monthly meeting Corporate Medical Affairs IIS Manager

16 Possibility 1: Rejection Corporate Medical Affairs IIS Manager IIS Review Group IIS Release Committee Monthly meeting  12 days after RG Investigator Local Medical Affairs IIS Process Rejection

17 Possibility 2: Work on it again Corporate Medical Affairs IIS Manager IIS Review Group IIS Release Committee Monthly meeting  12 days after RG Investigator Local Medical Affairs Next month RG Next month RC IIS Process Comments

18 Corporate Medical Affairs Study in database Info to local Medical Affairs Info to CTSU Info to PK Possibility 3: Released Corporate Medical Affairs IIS Manager IIS Review Group IIS Release Committee Monthly meeting  12 days after RG Investigator Local Medical Affairs Activation of internal operation system IIS Process

19 Study preparation Info to investigator Protocol by investigator Plausibility check of protocol by company Contract Implementation of study Tracking Report and publication Investigator Local Medical Affairs IIS Process Local process

BI's challenges of doing IIS Loss of control about your trials and data Difficult planning of timelines and budgets Potential negative publications about your products Budget limitation versus too many ideas Patent expiry Loss of motivation of investigator